Bone Health Management in Advanced Prostate Cancer on Long-Term Androgen Deprivation Therapy

Key Takeaways:

• Androgen deprivation therapy (ADT) accelerates bone mineral density (BMD) loss to up to approximately 4.6% in the first year. Fracture risk rises accordingly.
• Two clinical questions arise on long-term ADT: osteoporosis prevention at osteoporosis-indicated dosing, and skeletal-related event (SRE) prevention in bone-metastatic disease at higher dosing per pivotal trial evidence.
• Bone health on long-term ADT often falls between disciplines. Integration with primary care, endocrinology, or a survivorship pathway is vital.

Long-term androgen deprivation therapy (ADT) is foundational across the advanced prostate cancer treatment landscape. Its bone health consequences are well characterized but may be under-addressed in oncology consultations focused on systemic therapy decisions.¹

The bone-health conversation on ADT presents 2 distinct clinical questions – one rooted in osteoporosis biology, the other in bone-metastasis biology – and the indications and dosing of bone-modifying therapy differ between them. Both belong in the long-term management plan.¹

Bone mineral density loss on ADT

ADT accelerates bone resorption and net bone mineral density (BMD) loss substantially above the rate of normal male aging. Up to approximately 5% of total hip, femoral neck, and lumbar spine BMD loss has been reported in prostate cancer patients without bone metastases during the first year of ADT. This exceeds the 1 to 2% range observed in postmenopausal women and is well above the 0.5% baseline of normal male aging.²

Sustained ADT extends this trajectory, thereby amplifying fracture risk. The Cancer Care Ontario / ASCO-endorsed prostate-cancer-specific bone-health guideline recommends bone-modifying therapy in men receiving ADT at high fracture risk. Risk can be estimated using validated tools such as the Fracture Risk Assessment Tool (FRAX).¹

Treatment thresholds in the broader osteoporosis literature include a T-score of -2.5 or lower at the femoral neck, total hip, or lumbar spine, or a FRAX 10-year probability of at least 20% for major osteoporotic fracture or at least 3% for hip fracture.^3,4

The American Urological Association (AUA) Advanced Prostate Cancer guideline similarly recommends that clinicians discuss osteoporosis risk associated with ADT, assess fragility fracture risk, and offer preventive bone-modifying therapy in patients at high fracture risk.⁵

Osteoporosis vs skeletal-related event prevention

The first clinical question – osteoporosis prevention independent of bone-metastasis status – uses bone-modifying therapy at the osteoporosis-indicated dosing. ASCO/CCO recommends denosumab at the osteoporosis-indicated dose (60 mg subcutaneously every 6 months) in men with nonmetastatic prostate cancer at high fracture risk receiving ADT, with bisphosphonates (oral or intravenous) as reasonable alternatives.^1,6

Baseline dual-energy X-ray absorptiometry (DXA) at ADT initiation, ongoing FRAX-based risk assessment, calcium and vitamin D adequacy, weight-bearing and resistance exercise, smoking cessation, and alcohol moderation should all be part of the treatment plan as well.^1,3,4

The second clinical question – skeletal-related event (SRE) prevention in patients with bone metastases – uses bone-modifying therapy at meaningfully higher dosing. In a phase 3 trial of 1,904 men with bone metastases from castration-resistant prostate cancer, denosumab (120 mg subcutaneously every 4 weeks) was superior to zoledronic acid (4 mg intravenously every 4 weeks) for time to first on-study SRE (median 20.7 vs 17.1 months; hazard ratio 0.82, 95% CI 0.71–0.95; p = 0.008 for superiority).^5-7

Both class-level options are recommended for SRE prevention in metastatic castration-resistant prostate cancer per the AUA Advanced Prostate Cancer guideline (Moderate Recommendation, Grade B), the ASCO/CCO endorsement, and NCCN guidance.^1,4,8

The dosing for SRE prevention is higher and more frequent than the osteoporosis-indication dosing – the 2 indications should not be conflated in the choice of agent or schedule.^1,5

Bone-modifying therapy safety

Class-level safety considerations frame appropriate patient selection and monitoring. Hypocalcemia is more frequent with denosumab than zoledronic acid (13% vs 6% in the pivotal CRPC SRE-prevention trial; p < 0.0001).⁸

Osteonecrosis of the jaw (ONJ) occurred infrequently in both arms (2% denosumab vs 1% zoledronic acid). Dental assessment before initiation and ongoing oral-health attention are part of standard supportive care.^1,8

Atypical femur fracture is a recognized class consideration with long-term use. Renal dose adjustment is required for zoledronic acid based on creatinine clearance.^6,7

Calcium and vitamin D supplementation are required before and during therapy – the pivotal SRE-prevention trials required calcium ≥ 500 mg and vitamin D ≥ 400 IU daily, and both PI labels carry similar supplementation guidance. Broader osteoporosis guidelines reference higher daily doses for general osteoporosis management.^1,4,6,7

Long-term monitoring

Baseline DXA at ADT initiation, FRAX-based fracture risk assessment, calcium and vitamin D adequacy, and routine attention to falls and modifiable risk factors are all recommended in a patient’s long-term monitoring plan. Repeat BMD testing every 1 to 2 years is reasonable based on baseline risk and treatment intensity.^1-3

Where bone metastases are present, the conversation shifts to SRE prevention at the indicated higher dosing. Integration with primary care, endocrinology, or a survivorship pathway helps ensure the bone-health dimension does not fall between disciplines.